Sera Prognostics, Inc.

Sera Prognostics, Inc.

SERA·NASDAQ

$2.22

+8.3%
HealthcareMedical - Diagnostics & Research

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

At a Glance

Live Snapshot
Market Cap$84.78M
EPS-0.6700
P/E Ratio-3.31
Earnings Date08/05/2026

sera

Net Interest Income

Last Annual Value

4.58M

3-Year CAGR

126%

5-Year CAGR

35%

10-Year CAGR

16%

Sera Prognostics, Inc.

Sera Prognostics, Inc. Competitors Analysis of Net Interest Income

SERA · NASDAQ
CompanyNet Interest Income
CAGR 3Y
CAGR 5Y
CAGR 10Y
4.58M
42.4%N/AN/A 
419.00K
-53.7%N/AN/A
-4.48M
N/AN/AN/A
3.38M
42.6%N/AN/A
DCGO logo
DocGo Inc.
NASDAQ:DCGO
-1.01M
N/AN/AN/A
0.00
N/AN/AN/A
-109.00K
N/AN/AN/A
4.56M
459.6%369.4%N/A
-16.20M
N/AN/AN/A
364.00K
257.0%N/AN/A
-489.05K
N/AN/AN/A
Sera Prognostics, Inc.

Sera Prognostics, Inc. Fair Value Envelope

SERA · NASDAQ

Our analysis suggests that SERA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $2.22, this represents a potential HIDDEN relative to our calculated worth for Sera Prognostics, Inc..

Intrinsic Value
Current Price: $2.22